The US Opioid Epidemic and Its Impact on US General Practice Veterinarians

Lori Kogan*, Peter Hellyer1, Mark Rishniw2 and Regina Schoenfeld-Tacher3

1 Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States, 2 Veterinary Information Network, Davis, CA, United States, 3 Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States

Objective: To assess the impact of the human opioid epidemic and associated shortages in drug supply on US general practice veterinarians.

Design: Cross-sectional study.

Sample: Members of the Veterinary Information Network (VIN).

Procedures: An electronic survey was used to examine veterinarians’ views regarding opioid use in veterinary medicine and the impact of the opioid shortage on the provision of care. The survey was distributed via the VIN data collection portal from October 12–November 6, 2018.

Results: 697 veterinarians completed the survey. Most (99.7%) reported using, dispensing or prescribing opioids in veterinary practice. The most commonly used opioids were buprenorphine, tramadol and butorphanol. While most veterinarians (83.3%) reported difficulty in ordering opioids over the last 6 months, this decreased to 59.0% in the last month. The most difficult drugs to obtain were hydromorphone, morphine, injectable fentanyl, and oxymorphone. The reported rate of difficulty in obtaining all these drugs lessened over time. However, the opioid shortage caused significant difficulty in providing appropriate pain management for 41.1% of participants, and affected the ability of 44.8% of respondents to provide optimal anesthesia.

Conclusions and Clinical Relevance: Veterinarians’ ability to provide opioids for their patients has been impacted by the opioid shortage, with a greater impact on full mu opioid agonists as compared to drugs like butorphanol, buprenorphine, and tramadol. The results confirm the important role of opioid analgesics in the delivery of modern veterinary medicine and highlight the importance of medical health professionals being able to access these critical medications.

Keywords: opioid, veterinary, shortage, pain management, anesthesia

INTRODUCTION

Anecdotal evidence suggests that veterinarians have been struggling to obtain sufficient quantities of opioid analgesics for their patients. The apparent shortage of opioids may be due to multiple factors, such as manufacturing shortages and changes in compounding regulations; however, the opioid epidemic stands out as a significant contributing factor. According to
the National Institute on Drug Abuse (https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis), the Opioid Overdose Crisis (also known as the opioid crisis) has the following characteristics as of January 2019: “Every day, more than 130 people in the United States die after overdosing on opioids (1). The misuse of and addiction to opioids—including prescription pain relievers, heroin, and synthetic opioids such as fentanyl—is a serious national crisis that affects public health as well as social and economic welfare. The Centers for Disease Control and Prevention estimates that the total ‘economic burden’ of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement (2).”

In order to understand the impact of the opioid crisis on veterinary medicine it is vital to understand the role that human medicine and the well-intentioned desire to control pain in people contributed to where we are at now. The United States is in the midst of an opioid addiction epidemic (1–8) while simultaneously experiencing a shortage of opioids for use in legitimate medical situations, including the delivery of veterinary medicine. A wide variety of opioids are used in veterinary medicine to provide pain relief and as part of a balanced anesthetic protocol, including butorphanol, buprenorphine, fentanyl, hydromorphone, methadone, and morphine (9). There are numerous anecdotal stories of pet owners seeking opioids from veterinarians for their own use as well as owners requesting opioids for their pets when they are not needed or recommended (10). In response to this crisis, many states are passing laws to help monitor opioid prescriptions. In several states, professionals (including veterinarians) are now required to check the prescription drug monitoring program (PMP, a statewide database) and potentially notify authorities if a client meets specific criteria. Other states have begun limiting opioid prescriptions to 5–7 days (11).

A recent survey of 189 Colorado veterinarians found that 40% of respondents were unsure if there was an opioid problem in their community, but 62% felt that they have a role in preventing opioid misuse. Additionally, 44% of respondents were aware of opioid abuse or misuse by either a client or staff member and 13% were aware of a client who had intentionally made an animal ill or injured (or appear ill or injured) to obtain opioid medications (12). The researchers suggested that additional resources should be made available for tracking and surveillance, education, and further research.

In an effort to help support veterinarians, FDA commissioner Scott Gottlieb published a statement in August 2018 offering a resource to help veterinarians responsibly prescribe opioids (13). The resource includes suggestions to follow all state and federal regulations when ordering and prescribing opioids, use non-opioids when possible, educate pet owners on the risks of opioids, and educate oneself about opioid abuse—including signs/symptoms and a plan about how to proceed if they encounter opioid diversion or abuse (14). Additional opioid-related resources for veterinarians, created by the AVMA, include a list of states’ PMPs and continuing education related to opioids, a resource to help veterinarians identify “vet shopping” and drug diversion, and the AVMA’s policy on the veterinarian’s role in addressing the opioid epidemic (15).

These resources and guidelines were created because there are times when opioids are the best medical choice and ensuring that veterinarians are able to provide these medications to their patients is critically important. Paradoxically, in the presence of an opioid crisis anecdotal stories suggest that veterinarians are struggling to obtain opioids for their patients. This current study is the first one designed to assess how the opioid crisis has affected general practice veterinarians and their ability to provide optimal treatment to their clients.

**MATERIALS AND METHODS**

An anonymous online survey was created, in collaboration with VIN (an online veterinary community), to evaluate veterinarians’ views regarding opioids and the impact of the opioid shortage on the practice of veterinary medicine. The survey was created and tested by researchers at Colorado State University and VIN. After the survey was created, an online distribution was arranged for a small sample of VIN members in order to pilot the survey. They assessed the survey for appropriate branching and question flow, ambiguity, and potentially missing or inappropriate response options. Their feedback was analyzed, and incorporated into the final version of the survey. A link to the survey was distributed via an email invitation to all VIN members (n ∼ 35,000), and access was made available from October 12–November 6, 2018. US VIN members practice in all 50 US states, have an average age of 45.5 and are approximately 69% female. The authors believe that VIN membership is reflective of the veterinary profession at large. A follow-up message was sent 2 weeks after the initial invitation. Only data from respondents who stated they currently practice general veterinary medicine in the US were included in the study. The study was categorized as exempt by Colorado State University’s Institutional Review Board. Because this was an anonymous survey, written informed consent was not required. An introductory statement explained the study and indicated to potential participants that consent was implied by completing the survey.

The survey was administered directly via the VIN data collection portal, and branching logic was used to display only questions relevant to each participant. The first two questions were screening tools to ensure respondents were general practitioners practicing in the US. Veterinarians who self-identified as not in general practice (e.g., specialists) or did not practice in the US were eliminated from further analysis. The body of the survey consisted primarily of short questions, for which participants were able to select one or more specific options to represent their experiences and perceptions regarding opioid use, prescribing and dispensing. Free-text boxes were provided for participants to enter brief alternative answers when none of the listed options applied to them. A final question at the
TABLE 1 | Reported usage of common opioids by 697 veterinarians.

| Opioid           | Reported number of veterinarians using in practice |
|------------------|---------------------------------------------------|
| Buprenorphine    | 669 (96.0%)                                       |
| Tramadol         | 633 (90.8%)                                       |
| Butorphanol      | 631 (90.5%)                                       |
| Hydromorphone    | 500 (71.7%)                                       |
| Hydrocodone      | 428 (61.4%)                                       |
| Morphine         | 310 (44.5%)                                       |
| Fentanyl patch   | 190 (27.3%)                                       |
| Fentanyl injectable | 149 (21.4%)                                    |
| Methadone        | 76 (10.9%)                                        |
| Oxydormorphone   | 39 (5.6%)                                         |

TABLE 2 | Veterinarians’ reported frequency of prescribing specific opioids in veterinary practice.

| Opioid           | Prescribe frequently | Prescribe infrequently | Don’t prescribe |
|------------------|----------------------|------------------------|-----------------|
| Tramadol (n = 458) | 245 (53.5%)          | 139 (30.3%)            | 74 (16.2%)      |
| Buprenorphine (n = 475) | 126 (26.5%)       | 74 (15.6%)             | 275 (57.9%)     |
| Hydrocodone (n = 342) | 98 (28.7%)          | 197 (57.6%)            | 47 (13.7%)      |
| Fentanyl patch (n = 141) | 9 (6.4%)          | 55 (39.0%)             | 77 (54.6%)      |
| Butorphanol (n = 439) | 22 (5.0%)           | 62 (14.1%)             | 355 (80.9%)     |
| Methadone (n = 51)  | 2 (3.9%)             | 3 (5.9%)               | 46 (90.2%)      |
| Fentanyl injectable (n = 95) | 3 (3.2%)        | 4 (4.2%)                | 88 (92.6%)      |
| Hydromorphone (n = 351) | 10 (2.8%)          | 12 (3.4%)               | 329 (93.7%)     |
| Morphine (n = 214)   | 4 (1.9%)             | 7 (3.3%)                | 203 (94.9%)     |
| Oxydormorphone (n = 27) | -                | 2 (7.4%)                | 25 (92.6%)      |

RESULTS

Opioid Use

The number of respondents who were general practitioners practicing in the US, and therefore eligible for analysis, was 697. Nearly all respondents indicated they use, dispense or prescribe opioids (695/697; 99.7%). Participants were asked to indicate in what ways they work with opioids (prescribe, dispense, or use in clinic). The most common response was use in clinic (682, 97.8%), followed by dispense to clients (560, 80.3%), and prescribe or dispense from a list of the most common opioids. The most commonly used opioids were Buprenorphine, Tramadol, and Butorphanol (Table 1).

For each opioid, participants were asked to specify how they interfered with the drug: via use in clinic, prescribing to patients or dispensing to clients (or any combination of the three). For all drugs participants reported using in one of these three ways, they were asked to indicate how frequently they prescribed (Table 2) used in the clinic (Table 3) and dispensed (Table 4).

Next, participants who reported ordering and using opioids in the clinic were asked if they had experienced difficulties in obtaining opioids for use in the clinic or dispensing to clients in either the last 6 months or last 30 days. Difficulties obtaining opioids in the last 6 months (n = 682) was reported by 568, 83.3%. Fewer practitioners (101, 14.8%) reported no difficulties, and 13 (1.9%) said they did not know. Difficulties in the last 30 days (n = 669) was reported by 395 (59.0%), with 207 (30.9%) reporting not experiencing recent difficulties, and 67 (10.0%) reporting they did not know.

Similarly, participants who reported prescribing opioids to clients were asked to indicate if they have had challenges in the last 6 months (n = 485) or the last 30 days (n = 477). Reports of difficulties in the last 6 months were reported by 141 (29.1%); with 322 (66.4%) reporting no difficulties, and 22 (4.5%) saying they do not know. When asked about challenges in the last 30 days, 103 (21.6%) reported challenges, 339 (71.1%) reported no challenges, and 35 (7.3%) said they did not know.

Impact of Opioid Shortage on Providing Appropriate Pain Management

Participants were asked to rate the impact of the opioid shortage (on a scale from 1—no difficulty to 10—significant difficulty) on being able to provide appropriate pain management to their patients and providing optimal anesthesia that utilizes opioids. These scores were divided into three groups: no/little difficulty (scores 1–3), moderate difficulty (4–7), and significant difficulty (scores 8–10). Participants reported high levels of difficulty in both these areas (Table 6).

When participants were asked if they have canceled or postponed any procedures due to the opioid shortage in the last 6 months (n = 638), 549 (86.1%) said no, 18 (2.8%) said not.

end of the survey allowed for free-text entry of any comments participants chose to make about the current opioid shortage.
TABLE 4 | Veterinarians’ reported frequency rates for dispensing specific opioids in a clinic setting.

| Opioid                  | Dispense frequently | Dispense infrequently | Don’t dispense |
|-------------------------|---------------------|-----------------------|----------------|
| Buprenorphine (n = 539) | 279 (51.8%)         | 180 (33.4%)           | 80 (14.8%)     |
| Tramadol (n = 524)      | 350 (66.8%)         | 151 (28.8%)           | 23 (4.4%)      |
| Hydrocodone (n = 369)   | 119 (22.2%)         | 137 (37.1%)           | 113 (30.6%)    |
| Fentanyl patch (n = 164)| 15 (9.1%)           | 59 (36.0%)            | 90 (54.9%)     |
| Butorphanol (n = 503)   | 25 (5.0%)           | 144 (28.6%)           | 334 (66.4%)    |
| Hydromorphone (n = 395) | 6 (1.5%)            | 21 (5.3%)             | 368 (93.2%)    |
| Methadone (n = 70)      | 1 (1.4%)            | 7 (10.0%)             | 62 (88.6%)     |
| Morphine (n = 240)      | 2 (0.8%)            | 14 (5.8%)             | 224 (93.3%)    |
| Oxymorphone (n = 34)    | –                   | 3 (8.8%)              | 31 (91.2%)     |
| Fentanyl injectable (n = 126)| –     | 5 (4.0%)              | 121 (96.0%)    |

TABLE 5 | Veterinarians’ reported difficulties obtaining specific opioids (only for those who said they use each of these drugs).

| Opioid*                  | Difficulties obtaining in last 6 months | Difficulties obtaining in last month | No difficulty obtaining |
|--------------------------|-----------------------------------------|-------------------------------------|-------------------------|
| Hydromorphone (n = 500)  | 408 (81.6%)                             | 184 (36.8%)                         | 53 (10.6%)              |
| Morphine (n = 310)       | 232 (74.8%)                             | 120 (38.7%)                         | 46 (14.8%)              |
| Fentanyl injectable (n = 149)| 107 (71.8%)                 | 34 (22.8%)                         | 31 (20.8%)              |
| Oxymorphone (n = 39)     | 28 (71.8%)                              | 15 (38.5%)                         | 9 (23.1%)               |
| Butorphanol (n = 631)    | 42 (6.7%)                               | 17 (2.7%)                          | 540 (85.6%)             |
| Buprenorphine (n = 669)  | 178 (26.6%)                             | 46 (6.9%)                          | 425 (65.0%)             |
| Hydrocodone (n = 428)    | 141 (32.9%)                             | 64 (15.0%)                         | 236 (55.1%)             |
| Methadone (n = 76)       | 44 (57.9%)                              | 28 (36.8%)                         | 16 (21.1%)              |
| Tramadol (n = 633)       | 27 (4.3%)                               | 13 (2.1%)                          | 572 (90.4%)             |
| Fentanyl patch (n = 190) | 47 (24.7%)                              | 14 (7.4%)                          | 128 (67.4%)             |

*Numbers in this column reflect the total number of participants who reported using each opioid. Two additional separate questions were asked about difficulties obtaining the opioid (in last 6 months and last month). These questions were not required and therefore not answered by all those who indicated they used the opioid.

applied, and 71 (11.1%) said yes. They were then asked if they had discussed the opioid shortage with clients in situations where their pet requires opioid treatment (n = 624). A total of 316 (50.6%) said no, 29 (4.6%) said not applicable, and 279 (44.7%) said yes.

Lastly, participants were asked if they were concerned about opioid diversion from their patients to people who work in the hospital (n = 691) or the pet’s owners (n = 694). The number of participants who reported concern for clinic workers was less than the concern about diversion among pet owners. Concern for diversion to people within the clinic was noted by 171 (24.7%) of participants, 485 (70.2%) said they were not concerned about diversion to people within the clinic, 28 (4.1%) said they had not thought about it, and 7 (1.0%) said it was not applicable. When asked if they were concerned about diversion to pet owners, 441 (63.5%) said yes they were concerned, 231 (33.3%) said they were not concerned, 13 (1.9%) said they had never thought about it, and 9 (1.3%) said it was not applicable.

TABLE 6 | Areas of clinical practice affected by the opioid shortage as reported by practicing veterinarians.

| Opioid shortage                  | No/little difficulty | Moderate difficulty | Significant difficulty |
|----------------------------------|----------------------|---------------------|-----------------------|
| Affected ability to provide appropriate pain management (n = 694) | 175 (25.2%)         | 234 (33.7%)        | 286 (41.1%)           |
| Affected ability to provide optimal anesthesia (n = 692)        | 184 (26.6%)         | 198 (28.6%)        | 310 (44.8%)           |

DISCUSSION

Despite the widespread focus on the epidemic of opioid overdose/abuse in humans, there is a concurrent, poorly described opioid shortage for legitimate veterinary clinical use. The reasons for the shortage of clinically used opioids are unclear; however, anecdotally it appears the shortages have made an impact on veterinarians who use opioids in their practice. This is the first survey to the authors’ knowledge to explore this issue. Of the 697 VIN members who completed the survey, 99.7% indicated they use, dispense, or prescribe opioids. This result is not surprising considering that opioids are a fundamental part of anesthetic protocols and acute pain management, especially in small animal patients (9, 16, 17). Buprenorphine, tramadol, and butorphanol were the most widely used opioids, reflecting the importance of these drugs in anesthetic, sedation, and acute pain management protocols as well as veterinarian comfort with using these opioids. Interestingly, morphine was used by 44.5% of respondents, probably reflecting morphine’s efficacy for moderate to severe pain, good sedative properties, and affordability (9, 16–19).

Of the drugs utilized by survey participants, tramadol was the most commonly prescribed for outpatient use (245 out of 458, 53.5%) followed by buprenorphine (126 out of 475, 26.5%) and hydrocodone (98 out of 342, 28.7%). Although not specifically explored in the survey, it is likely that hydrocodone is prescribed primarily for cough suppression rather than pain control (20). Buprenorphine is often a good choice for postoperative pain control in dogs and cats and has the advantages of long lasting analgesic effect (~8 h) and high bioavailability following transmucosal administration (21–24). Tramadol has gained popularity over several years for the treatment of acute and chronic pain in dogs and cats; however, its efficacy has been questioned recently (25, 26). It is possible that some dogs administered tramadol do not experience any significant pain control. The popularity of tramadol may be due in part to the lack of effective and practical alternatives and anecdotal evidence suggesting that it has analgesic properties in some dogs. The dispensing rate from the in-hospital pharmacy (as opposed to prescribing to an outside pharmacy) followed the same pattern for tramadol, buprenorphine, and hydrocodone.

In clinic administration of opioids was most common for butorphanol, buprenorphine, tramadol, and the mu opioid agonists (fentanyl, hydromorphine, methadone, morphine). Oxymorphone, also a mu opioid agonist, was used less frequently than the other mu agonists (8 out of 39, 20.5%), likely due
to a lack of widespread availability. It is not surprising that
the mu opioid agonists are used primarily in clinic since
they are available as injectable drugs and are commonly used
in anesthetic protocols, especially for painful procedures. The
greater frequency of mu-opioid agonist use in clinic compared
to relatively few times these drugs were prescribed or dispensed
may be due to concerns over having injectable opioids leave a
clinic, lack of efficacy of oral mu agonists in dogs and cats, and
veterinarian concern over diversion of potent opioid drugs.

Participants reported having difficulty in ordering opioids for
their clinic in the last 6 months (568 out of 682, 83.3%) and in
the last 30 days (395 out of 669, 59%) suggesting that the opioid
shortage may be improving. When asked about the difficulty in
prescribing opioids for their patients, 141 out of 485 (29.1%) had
erperienced difficulty in the last 6 months, and 103 out of
485 (21.6%) had experienced difficulty in the last 30 days. The
difficulty in prescribing opioids mirrored the experience with
ordering drugs for in clinic use in that the difficulty seems to
have improved in the last 30 days as compared to 6 months
ago. Interestingly, it was more difficult for these veterinarians
to order opioids for their clinic than it was to prescribe them
for their patients, possibly reflecting the greater buying power
that many pharmacies have compared to individual in clinic
veterinary pharmacies.

For veterinarians experiencing difficulty ordering opioids
over the past 6 months, hydromorphone, morphine, injectable
fentanyl, oxymorphone, and fentanyl patches were the most
difficult to obtain. These results are not surprising considering
that all of these drugs are Schedule II drugs indicating a
legitimate medical use with a high potential for abuse, with
use potentially leading to severe psychological or physical
dependence (27). Although only 190 respondents ordered
fentanyl patches, 47 (24.7%) experienced difficulty ordering
fentanyl in this formulation. Fentanyl patches seem to have lost
popularity in veterinary medicine over the last several years as
studies have documented inconsistent transdermal absorption
(28–31). Anecdotally, veterinarians appear to be concerned about
sending patients home with a transdermal fentanyl patch applied
due to the potential for diversion of the powerful opioid in
the patch.

Participants were asked about the impact of the opioid
shortage on their ability to practice veterinary medicine.
Specifically, the opioid shortage impacted the veterinarian’s
ability to provide appropriate pain management significantly
(285 out of 694, 41.1%) or moderately (234 out of 694, 33.7%).
Similarly, the opioid shortage affected their ability to provide
optimal anesthesia significantly (310 out of 629, 44.8%) and
moderately (198/692, 28.6%). When asked if procedures were
canceled or postponed due to an opioid shortage, 549 out of
638 (86.1%) said no. This raises an interesting question in
terms of how optimal analgesia or anesthesia was performed in
the presence of an opioid shortage. In the author's experience,
multimodal analgesic and anesthetic plans were typically put
in place involving approaches such as infusions of ketamine,
lidocaine, butorphanol, and/or dexmedetomidine and the use of
regional anesthetic blocks (9, 32). It would be interesting
to understand how veterinarians filled the gap left by the
opioid shortage.

In terms of the potential for diversion of opioids, participants
were more concerned about diversion of opioids from pets to
clients (or presumably clients’ friend or family) than to hospital
staff. Only 171 out of 691 (24.7%) of participants were concerned
about potential diversion of opioids to clinic staff. Although
lower than the number concerned about diversion from pets
to clients (441 out of 691, 63.5%), these results suggest that
veterinarians are aware that individuals within their clinics
are just as susceptible to opioid addiction as the rest of the
population. It is not surprising that veterinarians would have a
greater level of trust for people they work with on a daily basis
as compared to some of their clients in terms of the potential
for diversion.

Limitations of this study are that the data was gathered via
an on-line survey and it is likely that those veterinarians which
were impacted by the opioid shortages are probably more likely
to complete the survey. In addition, the survey was administered
to VIN members and not the entire population of veterinarians.
A further limitation is that the survey was geared toward general
practitioners so that we do not know the impact of the shortages
on specialty practices.

The results of this study suggest that veterinarians have
been impacted by the opioid shortage, with a greater impact
on full mu opioid agonists as compared to drugs like
butorphanol, buprenorphine, and tramadol. The shortage has
had a moderate to significant impact on the delivery of
analgesic care and optimal anesthesia to veterinary patients.
In terms of dispensing or prescribing opioids, the impact
of the opioid shortage appears to have been greater on
the ability of the veterinarian to have the drugs available
to dispense from their own pharmacy. Importantly, these
results confirm the important role of opioid analgesics in
the delivery of modern veterinary medicine in spite of
significant societal problems associated with the overuse of
opioids. This is essentially the same as in human health
whereby opioids have an important and legitimate role in pain
management and anesthesia, and highlights the importance of
medical health professionals being able to access these critical
medications (33).

DATA AVAILABILITY

The datasets generated for this study are available on request to
the corresponding author.

AUTHOR CONTRIBUTIONS

LK, PH, and MR conceived the study and conducted the research.
RS-T helped write and prepare the manuscript.

ACKNOWLEDGMENTS

The authors would like to acknowledge VIN for their cooperation
in disseminating the survey.
REFERENCES

1. Anon. Opioid Crisis. Health Resources & Services Administration 2019. Available online at: https://www.hrsa.gov/opioids (accessed February 20, 2019).

2. Hedegaard H, Warner M, Minino AM. Drug Overdose Deaths in the United States, 1999-2016. Hayattsville, MD: NCHS Data Brief (2017). Available online at: https://www.cdc.gov/nchs/products/databriefs/db294.htm (accessed February 20, 2019).

3. Anon. Opioid Overdose; Data Overview. (2018). Available online at: https://www.cdc.gov/drugoverdose/data/index.html (accessed February 20, 2019).

4. Anon. Opioids. Bethesda, MD (2018). Available online at: https://www. drugabuse.gov/drugs-abuse/opioids (accessed February 20, 2019).

5. McCance-Katz E (SAMHSA/OAS). SAMHSA/HHS: An Update on the Opioid Crisis. (2018). Available online at: https://www.samhsa.gov/sites/default/files/aadot_2018_final.pdf (accessed February 20, 2019).

6. Anon. Prescription Opioid Data. Opioid Overdose (2018). Available online at: https://www.cdc.gov/drugoverdose/data/prescribing.html (accessed February 21, 2019).

7. Blozen BB. Opioids: A Growing Epidemic of Abuse, Vol. 8. American Nurse Today 2013. Available online at: https://www.americanurse today.com/prescription-opioids-a-growing-epidemic-of-abuse/ (accessed February 20, 2019).

8. Anon. Report of the International Narcotics Control Board for 2008. Vienna: United Nations (2009). Available online at: https://www.inch.org/documents/Publications/AnnualReports/AR2008/AR_08_English.pdf (accessed February 20, 2019).

9. Epstein ME, Rodan I, Grifffenhagen G, Kadrik J, Petty MC, Robertson SA, et al. 2015 AHA/AAPF pain management guidelines for dogs and cats. J Feline Med Surg. (2015) 17:251–72. doi: 10.1177/1098612X15572062

10. Shadde CC, Meyer JL. Pets, vets, and opioids. Am Vet. (2018). Available online at: https://www.americanveterinarian.com/journals/amvet/2018/apr2018/ pets-vets-and-opioids. (accessed February 22, 2019).

11. Anon. State Legislative Update January 2018. (2018). Available online at: https://www.avma.org/Advocacy/StateAndLocal/Documents/SLU-Jan2018.pdf (accessed February 21, 2019).

12. Mason DS, Tenney L, Hellyer PW, Newman LS. Prescription opioid epidemic: do veterinarians have a dog in the fight? Am J Public Health. (2018) 108:1162–3. doi: 10.2105/AJPH.2018.304603

13. Anon. Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s New Resource Guide to Support Responsible Opioid Prescribing for Pain Management in Animals. Silver Spring, MD (2018). Available online at: https://www.fda.gov/NewsEvents/PressAnnouncements/ucm617507.htm (accessed February 20, 2019).

14. Anon. The Opioid Epidemic: What Veterinarians Need to Know. US Food Drug Administration (2018). Available online at: https://www.fda.gov/AnimalVetryinary/ResourcesforYou/ucm616944.htm (accessed February 20, 2019).

15. Anon. Opioid Resources for Veterinarians. American Veterinary Medical Association (2018). Available online at: https://www.avma.org/KB/Resources/Reference/Pages/opioid-resources-for-veterinarians.aspx (accessed February 20, 2019).

16. Mwangi WE, Mogoa EM, Mwangi JN, Muthia PG, Mbugua SW. A systematic review of analgesia practices in dogs undergoing ovariohysterectomy. Vet World. (2018) 11:1725–35. doi: 10.14202/vetworld.2018.1725-1735

17. Quandt J. Analgesia, anesthesia, and chemical restraint in the emergent small animal patient. Vet Clin North Am Small Anim Pract. (2013) 43:941–53. doi: 10.1016/j.cvsm.2013.03.008

18. Shah MD, Yates D, Hunt J, Murrell JC. A comparison between methadone and buprenorphine for perioperative analgesia in dogs undergoing ovariohysterectomy. J Small Anim Pract. (2018) 59:539–46. doi: 10.1111/jsap.12859

19. Beckman B. Anesthesia and pain management for small animals. Vet Clin North Am Small Anim Pract. (2013) 43:669–88. doi: 10.1016/j.cvsm.2013.02.006

20. Heffernan AE, Katz EM, Sun Y, Rendahl AK, Conzemius MG. Once daily oral extended-release hydrocodone as analgesia following tibial plateau leveling osteotomy in dogs. Vet Surg. (2018) 47:516–23. doi: 10.1111/jvs.12792

21. Steagall PVM, Monteiro-Stegall BP, Taylor PM. A review of the studies using buprenorphine in cats. J Vet Intern Med. (2014) 28:762–70. doi: 10.1111/jvim.12346

22. Stathopoulou T-R, Kouki M, Pympend BH, Johnston A, Papadimitriou S, Pelligand L. Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease. J Feline Med Surg. (2018) 20:704–10. doi: 10.1177/1098612X1727234

23. Ko JC, Freeman LJ, Barletta M, Weil AB, Payton ME, Johnson BM, et al. Efficacy of oral transmucosal and intravenous administration of buprenorphine before surgery for postoperative analgesia in dogs undergoing ovariohysterectomy. J Am Vet Med Assoc. (2011) 238:318–28. doi: 10.2460/javma.238.3.3138

24. Gulleld BM, Messenger KM, Cornell KK, Lindell H, Schmied CW. Pharmacokinetic comparison of two buprenorphine formulations after buccal administration in healthy male cats. J Feline Med Surg. (2018) 20:312–8. doi: 10.1177/1098612X17108843

25. Guedes AGP, Meadows JM, Pympend BH, Johnson EG. Evaluation of tramadol for treatment of osteoarthritis in geriatric cats. J Am Vet Med Assoc. (2018) 252:565–71. doi: 10.2460/javma.252.5.565

26. Budsberg SC, Torres BT, Kleine SA, Sandberg GS, Berjeski AS. Lack of effectiveness of tramadol hydrochloride for the treatment of pain and joint dysfunction in dogs with chronic osteoarthritis. J Am Vet Med Assoc. (2018) 252:427–32. doi: 10.2460/javma.252.4.427

27. Anon. Drug Scheduling. United States Drug Enforcement Administration. Available online at: https://www.dea.gov/drug-scheduling (accessed February 21, 2019).

28. Egger CM, Glerum LE, Allen SW, Haag M. Plasma fentanyl concentrations in awake cats and cats undergoing anesthesia and ovariohysterectomy using transdermal administration. Vet Anaesth Analg. (2003) 30:229–36. doi: 10.1046/j.1467-2995.2003.00109.x

29. Lee DD, Papich MG, Hardie EM. Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats: animal handlers. Am J Vet Res. (2000) 61:672–7. doi: 10.2460/ajvr.2000.61.672

30. Kukanich B, Clark TP. The history and pharmacology of fentanyl: relevance to a novel, long-acting transdermal fentanyl solution newly approved for use in dogs. J Vet Pharmacol Ther. (2012) 35:3–19. doi: 10.1111/j.1365-2885.2012.01416.x

31. Franks JN, Boothe HW, Taylor L, Geller S, Carroll GL, Cracas V, et al. Evaluation of transdermal fentanyl patches for analgesia in cats undergoing onychectomy. J Am Vet Med Assoc. (2000) 217:1013–20. doi: 10.2460/javma.2000.217.1013

32. Lascelles BDx, Kirkby Shaw K. An extended release local anesthetic: potential for future use in veterinary surgical patients? Vet Med Sci. (2016) 2:229–38. doi: 10.1002/vms3.43

33. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. J Am Med Assoc. (2018) 315:1624–45. doi: 10.1001/jama.2016.1464

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Kogan, Hellyer, Rishniw and Schoenfeld-Tacher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.